Financial Performance Summary - In 2025, the company achieved operating revenue of 288.27 million RMB, a decrease of 4.99% compared to the previous year [3] - The net profit attributable to the parent company was a loss of 19.09 million RMB, which represents a reduction in losses by 57.33% year-on-year [3] - Total assets at the end of the reporting period were 1.54 billion RMB, a decrease of 0.71% from the beginning of the year [3] - The equity attributable to the parent company was 1.39 billion RMB, down 1.47% from the beginning of the year [3] Operational Factors - The company continued to expand into new areas of biopharmaceutical technology, enhancing product market competitiveness and optimizing marketing strategies [4] - Despite increased sales volume due to entry into large aquaculture supply chains, revenue and gross margin slightly declined due to competitive pricing pressures in the animal health industry [4] - Delays in customer payments led to an increase in accounts receivable and higher credit impairment losses [4] - The company adjusted its operational strategy, focusing on customer needs and achieving progress in the development of multi-valent vaccines [4] Investment and Future Plans - The company invested in a stake in an innovative drug company, Yangzhou Shizhi Source Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [5] - The company plans to gain controlling interest in Shizhi Source through its wholly-owned subsidiary, Shanghai Bentiancheng Biotechnology Co., Ltd., integrating it into the consolidated financial statements [5] - Future plans include leveraging biotechnological advantages to accelerate the development and launch of innovative drugs, including treatments for HIV and allergy monoclonal antibodies [6] Credit Impairment Provision - The company plans to recognize a credit impairment provision of 12.76 million RMB for the year 2025 [11] - This provision is based on expected credit losses from accounts receivable, notes receivable, and other receivables [11] - The impact of this provision on the company's total profit for 2025 is estimated to be 12.76 million RMB, excluding tax effects [12]

Core Viewpoint - The company expects a net profit of approximately -20 million yuan for the year 2025, which represents a reduction in losses of about 24.74 million yuan compared to the previous year, indicating a year-on-year loss reduction of approximately 55% [1] Group 1: Financial Performance - The company's net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses are both expected to show losses for 2025 [1] - The overall sales revenue and gross margin have slightly decreased compared to the same period last year due to intense competition in the animal health industry and a decline in vaccine product prices [1] - The increase in accounts receivable due to delayed customer payments has led to a rise in credit impairment losses [1] - The depreciation of fixed assets has increased following the commissioning of a new vaccine workshop [1] Group 2: Strategic Developments - The company is actively expanding into new areas of biopharmaceutical technology and optimizing its marketing layout, resulting in increased product sales volume [1] - The company has made significant progress in the research and development of multi-valent vaccines, with new products such as the swine fever genetic engineering subunit vaccine and the swine streptococcus disease/infectious pleuropneumonia bivalent vaccine being launched [1] - The total period expenses have significantly decreased compared to the previous year, contributing to a reduction in net profit losses by approximately 55% [1] Group 3: Investment and Future Plans - The company has invested in a stake in the innovative drug company Yangzhou Shizhi Yuan Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [2] - The company plans to acquire a controlling stake in Shizhi Yuan to synergize its human and animal health businesses, leveraging its advanced biotechnology and production advantages in the human innovative drug sector [2] - The company aims to expedite the research and development and market launch of several innovative drugs, including monoclonal antibodies for AIDS [2]

Core Viewpoint - The company expects a net profit of approximately -20 million yuan for the year 2025, which represents a reduction in losses by about 24.74 million yuan compared to the previous year, indicating a year-on-year loss reduction of approximately 55% [1] Group 1: Financial Performance - The company's net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses both showed losses during the reporting period [1] - The overall sales revenue and gross margin slightly decreased compared to the same period last year due to intense competition in the animal health industry and a decline in vaccine product prices [1] - The increase in accounts receivable due to delayed customer payments led to a rise in credit impairment losses [1] Group 2: Strategic Developments - The company is actively expanding into new areas of biopharmaceutical technology and optimizing its marketing layout, resulting in increased product sales volume [1] - The company has made significant progress in the research and development of multi-valent vaccines, with new products such as the swine fever genetic engineering subunit vaccine and the swine streptococcus disease/infectious pleuropneumonia bivalent vaccine being launched [1] - The total period expenses have significantly decreased compared to the previous year, contributing to a reduction in net profit losses by approximately 55% [1] Group 3: Investment and Future Plans - The company has invested in a stake in the innovative drug company Yangzhou Shizhi Yuan Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [2] - The company plans to acquire a controlling stake in Shizhi Yuan to synergize its human medicine and animal health businesses, leveraging its advanced biotechnological and production capabilities for the development of innovative drugs [2] - The company aims to expedite the research and market launch of several innovative drugs, including monoclonal antibodies for AIDS [2]